{"transactions":[{"id":905316,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-14T01:00:45.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":226875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":226875,"derivative":{"exercise_price":14.81,"expiration_date":"2036-02-11","underlying":"Common Stock","underlying_shares":226875},"source":{"system":"sec-edgar","filing":"0001193125-26-052056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526052056/ownership.xml","form_type":"4"}},{"id":905315,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-14T01:00:45.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":37813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":37813,"source":{"system":"sec-edgar","filing":"0001193125-26-052056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526052056/ownership.xml","form_type":"4"}},{"id":1088072,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-14T23:12:40.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":526000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 526,000 shares of the Issuer's common stock, one quarter of which will vest on July 14, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":526000,"derivative":{"exercise_price":9,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":526000},"source":{"system":"sec-edgar","filing":"0000950170-25-095668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000095017025095668/ownership.xml","form_type":"4"}},{"id":1643254,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T16:00:26.000Z","date":"2024-02-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":332114,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.0347,"underlying":"Common Stock","underlying_shares":332114},"source":{"system":"sec-edgar","filing":"0001104659-24-023551","document":"tm246087-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023551/tm246087-1_4seq1.xml","form_type":"4"}},{"id":1643253,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Restricted Stock Units","published_at":"2024-02-14T16:00:26.000Z","date":"2024-02-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Issuer restricted stock unit (\"Issuer RSU\") represents a contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-24-023551","document":"tm246087-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023551/tm246087-1_4seq1.xml","form_type":"4"}},{"id":1643252,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2024-02-14T16:00:26.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":8150.225,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 2,008 shares acquired under the Issuer's employee stock purchase plan on May 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company (\"Parent\") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the \"Effective Time\") with the Issuer surviving the merger."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the \"Cash Amount\"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a \"CVR\"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-023551","document":"tm246087-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465924023551/tm246087-1_4seq1.xml","form_type":"4"}},{"id":1979734,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-02T07:00:48.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date."}],"balance_after":17500,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-23-027624","document":"tm237858-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465923027624/tm237858-2_4seq1.xml","form_type":"4"}},{"id":2003669,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-21T07:01:22.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 17, 2024 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer."}],"balance_after":105000,"derivative":{"exercise_price":11.42,"expiration_date":"2033-02-17","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001104659-23-023506","document":"tm237110-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465923023506/tm237110-2_4seq1.xml","form_type":"4"}},{"id":2100117,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T16:35:05.000Z","date":"2022-11-30","kind":"purchase","acquired":true,"shares":1502.189,"price":6.657,"value":10000.072173,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $6.56 to $6.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,162 shares and 1,508 shares previously purchased under the Issuer's 2021 Employee Stock Purchase Plan on May 13, 2022 and November 14, 2022, respectively."}],"balance_after":6142.225,"source":{"system":"sec-edgar","filing":"0001104659-22-123686","document":"tm2231776-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465922123686/tm2231776-1_4seq1.xml","form_type":"4"}},{"id":2378771,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-23T20:00:22.000Z","date":"2022-02-18","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 18, 2023 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer."}],"balance_after":150000,"derivative":{"exercise_price":11.21,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-22-007498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000089924322007498/doc4.xml","form_type":"4"}},{"id":2461122,"issuer":{"id":94301,"kind":"organization","name":"Theseus Pharmaceuticals, Inc.","symbol":"THRX"},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-22T18:21:47.000Z","date":"2021-12-21","kind":"purchase","acquired":true,"shares":1970.036,"price":10.1521,"value":20000.0024756,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $10.09 to $10.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price."}],"balance_after":1970.036,"source":{"system":"sec-edgar","filing":"0000899243-21-049427","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745020/000089924321049427/doc4.xml","form_type":"4"}},{"id":2915390,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-06T21:49:34.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":230000,"derivative":{"exercise_price":2.99,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001453687-21-000015","document":"wf-form4_160996976014499.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000015/wf-form4_160996976014499.xml","form_type":"4"}},{"id":2915389,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-06T21:49:34.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025."}],"balance_after":38000,"source":{"system":"sec-edgar","filing":"0001453687-21-000015","document":"wf-form4_160996976014499.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368721000015/wf-form4_160996976014499.xml","form_type":"4"}},{"id":3088716,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-07-06T20:11:40.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% on July 1, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":2.84,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-081211","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000110465920081211/a4.xml","form_type":"4"}},{"id":3318307,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-07T01:07:07.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":140000,"derivative":{"exercise_price":2.3,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001453687-20-000010","document":"wf-form4_157835920999505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368720000010/wf-form4_157835920999505.xml","form_type":"4"}},{"id":3421774,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":66507,"kind":"person","name":"Dahms Bradford D.","position":1,"cik":"0001787307","reported_name":"Dahms Bradford D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-09-05T21:29:54.000Z","date":"2019-09-03","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% on September 3, 2020, and the remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":400000,"derivative":{"exercise_price":1.7,"expiration_date":"2029-09-02","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001453687-19-000133","document":"wf-form4_156771897844321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368719000133/wf-form4_156771897844321.xml","form_type":"4"}}]}